LY-2874455

N/A

Report date: 2025/06/05 20:00:13

NME

Base Information

Drug NameLY-2874455

Drug Alias NameFGF receptor inhibitor - Eli LillyLY-2874455

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionFibroblast growth factor receptor 4 antagonistsFibroblast growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonists +[4]

TargetsFibroblast growth factor receptor 4Fibroblast growth factor receptor 1Fibroblast growth factor receptor 3 +[4]

Therapy Area/IndicationsLeukemia, Myeloid, AcuteNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustraliaSouth Korea

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesEli Lilly And Company

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesEli Lilly And Company

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, AcuteNeoplasms

Other Information

ATC CodeN/A